ARWR Latest Press Releases

-- November 4, 2026 --

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity Business Wire 7:30 AM

-- November 3, 2026 --

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results Business Wire 4:00 PM

-- November 2, 2026 --

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026 Business Wire 7:30 AM

-- October 27, 2026 --

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO (Plozasiran) as a New Treatment Option to Reduce Triglycerides Business Wire 11:36 AM

-- October 14, 2026 --

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers Business Wire 7:30 AM

-- October 7, 2026 --

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia Business Wire 7:30 AM

-- September 29, 2026 --

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies Business Wire 8:07 AM

-- September 15, 2026 --

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia Business Wire 7:30 AM

-- September 3, 2026 --

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences Business Wire 7:30 AM

-- August 30, 2026 --

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia Business Wire 11:30 AM

-- August 24, 2026 --

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress Business Wire 7:30 AM

-- August 17, 2026 --

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO (plozasiran) as a New Treatment Option to Reduce Triglycerides Business Wire 9:33 AM

-- August 4, 2026 --

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results Business Wire 4:01 PM

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher Business Wire 4:00 PM

-- August 3, 2026 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- July 27, 2026 --

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia Business Wire 7:30 AM

-- July 22, 2026 --

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia Business Wire 7:30 AM

-- July 21, 2026 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results Business Wire 7:30 AM

-- June 22, 2026 --

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) Business Wire 12:33 PM

-- June 18, 2026 --

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars Business Wire 7:30 AM

Market Data Delayed 15 Minutes